These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27097701)

  • 1. Comparative In Vitro Efficacy of Doripenem and Imipenem Against Multi-Drug Resistant Pseudomonas aeruginosa.
    Wali N; Mirza IA
    J Coll Physicians Surg Pak; 2016 Apr; 26(4):297-301. PubMed ID: 27097701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Efficacy of Doripenem against Pseudomonas aeruginosa and Acinetobacter baumannii by E-Test.
    Gilani M; Munir T; Latif M; Rehman S; Ansari M; Hafeez A; Najeeb S; Saad N; Gilani M
    J Coll Physicians Surg Pak; 2015 Oct; 25(10):726-9. PubMed ID: 26454387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
    van der Bij AK; Mol M; van Westreenen M; Goessens WH; Pitout JD
    Scand J Infect Dis; 2011 Aug; 43(8):596-602. PubMed ID: 21506891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
    Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
    Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
    Firsov AA; Gilbert D; Greer K; Portnoy YA; Zinner SH
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1223-8. PubMed ID: 22203591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():109-16. PubMed ID: 23835967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro activity of doripenem and other carbapenems against Pseudomonas aeruginosa].
    Nicola F; García Ramírez D; Arduino S; Di Chiara M; Smayevsky J
    Rev Argent Microbiol; 2010; 42(3):193-8. PubMed ID: 21186673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
    Kakeya H; Yamada K; Nakaie K; Takizawa E; Okada Y; Fujita A; Nakamura Y; Abe J; Hirose A; Kaneko Y; Hino M
    Jpn J Antibiot; 2014 Aug; 67(4):241-8. PubMed ID: 25420320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
    Gelfand MS; Cleveland KO; Mazumder SA
    J Antimicrob Chemother; 2009 Jun; 63(6):1297-9. PubMed ID: 19369268
    [No Abstract]   [Full Text] [Related]  

  • 15. Antimicrobial resistance surveillance of doripenem in China.
    Li Y; Lv Y; Xue F; Zheng B; Liu J; Zhang J
    J Antibiot (Tokyo); 2015 Aug; 68(8):496-500. PubMed ID: 25850342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.
    Somily AM; Absar MM; Arshad MZ; Al Aska AI; Shakoor ZA; Fatani AJ; Siddiqui YM; Murray TS
    Saudi Med J; 2012 Jul; 33(7):750-5. PubMed ID: 22821309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):212-215. PubMed ID: 31174995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
    Gimeno C; Cantón R; García A; Gobernado M;
    Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.